The content on this site is intended for healthcare professionals only
Elahe Salehi speaks to ecancer at the APAO 2019 meeting in Boston about the treatment pathways used at The Dana-Farber Cancer Institute for patients with triple-negative breast cancer.
She references the results of the IMpassion130 clinical trial and the use of atezolizumab in combination with nab-paclitaxel is the standard of care used at the Dana-Farber Cancer Institute for their metastatic patients.
Salehi discusses the adverse events associated with immunotherapy which can result in a delay in therapy.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Overview of the management of HER2-low breast cancer patients
Management of HER2 positive metastatic breast cancer treatment algorithm
Post neoadjuvant management in BRCA mutant breast cancer patients
